Microarray expression profiles of long non-coding RNAs in germinal center-like diffuse large B-cell lymphoma

Abstract

Long non-coding RNAs (lncRNAs) are continuously transcribed and are involved in various cellular activities. However, their contributions to the occurrence and development of germinal center B-cell (GCB)-like diffuse large B-cell lymphoma (DLBCL) remain largely unknown. We applied microarray technology to profile the expression of lncRNAs in two different GCB-DLBCL cell lines (OCI-ly1 and OCI-ly19) and normal B lymphocytes. We demonstrated that 21,539 lncRNAs were expressed in all of the samples analyzed. This included 1,648 lncRNAs that showed a ≥2-fold upregulation and 2,671 lncRNAs that displayed a ≥2-fold downregulation in tumor cell lines (P<0.05). The expression levels of 8 lncRNAs were validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Bioinformatic analyses (Gene Ontology, pathway and network analysis) were performed to predict how the differentially expressed lncRNAs may function in GCB-DLBCL. Results from the pathway analysis suggested that totals of 64 and 62 biological pathways corresponded to upregulated and downregulated transcripts, respectively (P<0.05). Additionally, we constructed a lncRNA-mRNA network for the purpose of identifying specific coding genes which were co-expressed with 5 selected lncRNAs. Conclusively, our results may contribute to a better understanding of GCB-DLBCL pathogenesis.

Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma

“…Recent studies have identified hundreds of DEGs in DLBCL [5]. However, the results of these studies have contradictory or inconsistent data due to small sample size [6], tissue heterogeneity or produced from single cohort studies [7]. Integrating and re-analyzing published sequence data may help resolve these issues.…”

β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway

“…Cancer research and recent studies implicated that various lncRNAs are dysregulated in human malignancies. Aberrant expression of lncRNA is associated with the DLBCL patient's clinical characteristics and poor prognosis and can be applied to serve as a therapeutic target [16][17][18]. LncRNA HULC has been reported to play a crucial role in tumor carcinogenesis and progression.…”

“…Long non-coding RNA (lncRNA) that is greater than 200 nucleotides has been reported to be associated with the development of lymphoma, including DLBCL [16][17][18]. Aberrant expression of lncRNA is associated with DLBCL occurrence and development.…”

<p>Non-Coding RNAs in Diffuse Large B-Cell Lymphoma</p>

“…Among these differentially expressed lncRNAs, ENST00000424690, ENST00000425358, and NR_026892 were upregulated, and ENST00000464929 and ENST00000475089 were downregulated in DLBCL compared to RLN. 104 Moreover, Deng et al demonstrated that NEAT1_1 could serve as a useful diagnostic tool to differentiate between DLBCL and lymphadenitis. 112 Several studies have reported the connection between lncRNA expression patterns and subtype classification.…”